By Sneha S K Jan 9 (Reuters) - Schrodinger said on Friday it is collaborating with Eli Lilly to offer the pharmaceutical ...

Jan 9 (Reuters) - Schrodinger said on Friday it is collaborating with Eli Lilly to offer the pharmaceutical major's AI-based platform, TuneLab, on its drug ‌designing software. Integration of Lilly's ...

Schrodinger reported robust software and drug discovery revenue in the second quarter. Lilly's planned multi-billion-dollar acquisition of Morphic also provides another validation point for ...

Jan 9 : Schrodinger said on Friday it is collaborating with Eli Lilly to offer the pharmaceutical major's AI-based platform, TuneLab, on its drug designing software. Integration of Lilly's TuneLab ...

Jan 9 (Reuters) - Schrodinger (SDGR.O), opens new tab said on Friday it is collaborating with Eli Lilly (LLY.N), opens new tab to offer the pharmaceutical major's AI-based platform, TuneLab, on its ...

Schrodinger reported strong Q4 2023 results, but weak guidance for 2024, causing a significant drop in the share price. The demand environment continues to impact the software business, with growth ...